Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and the lives of patients worldwide.
INNOVATIVE TOPICAL THERAPIES FOR MILLIONS OF PATIENTS WORLDWIDE
The Oculis strategy is to build a specialty ophthalmology company unlike any other. Our plan is to:
- Further advance our lead candidates: OCS-01 as a new therapeutic option for DME and post-cataract inflammation and OCS-02 for front-of-the-eye inflammation.
- Develop a clinical pipeline of topical treatments for back and front-of the-eye disease based on internal development with our proprietary SNP technology and via complementary in-licensed assets
OCS-01 A POTENTIAL PARADIGM SHIFT IN DME TREATMENT
Our most advanced product candidate based on SNP technology is OCS-01, which is in clinical trials in patients with DME and in planning phase for potential front-of-the-eye indications.
If approved in DME, it has the potential to provide a new option for patients for whose current therapies are limited to intravitreal injections or implants.
TAKING TREATMENT FROM INJECTIONS TO DROPS FOR RETINAL DISEASES
Our novel technology provides an unprecedented technical advancement in ocular drug delivery, particularly for back-of-the-eye diseases that are currently managed by invasive methods such as intraocular injections or implants.